Overview

* Supernus Q3 2025 total rev rises 9% yr/yr, driven by growth products

* Company completed acquisition of Sage Therapeutics, contributing to collaboration revenue

* Operating loss in Q3 due to acquisition-related costs

Outlook

* Supernus raises full-year 2025 revenue guidance to $685 mln - $705 mln

* Company updates 2025 operating loss guidance to $(65) mln - $(75) mln

* Supernus expects 2025 adjusted operating earnings of $125 mln - $145 mln

Result Drivers

* GROWTH PRODUCTS - Combined revenues from Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO increased 52% to $149.2 mln, driving overall revenue growth

* ONAPGO LAUNCH - ONAPGO generated $6.8 mln in sales in its first full quarter post-launch, but supply constraints are limiting new patient starts

* SAGE ACQUISITION - Acquisition of Sage Therapeutics contributed $20.2 mln in collaboration revenue from ZURZUVAE

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $168.50

Product mln

Sales

Q3 $170 mln

Adjusted

Revenue

Q3 EPS -$0.80

Q3 -$60.23

Operatin mln

g

Earnings

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Supernus Pharmaceuticals Inc ( SUPN ) is $61.50, about 9.4% above its November 3 closing price of $55.70

* The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)